LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Lowered by StockNews.com

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Thursday.

A number of other analysts have also issued reports on the company. JMP Securities increased their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target for the company. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective for the company. Oppenheimer reissued an “outperform” rating and issued a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Finally, Barrington Research raised their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Trading Up 2.5 %

Shares of NASDAQ LMAT traded up $2.59 during midday trading on Thursday, reaching $105.87. 177,902 shares of the stock were exchanged, compared to its average volume of 124,221. The company has a market capitalization of $2.38 billion, a P/E ratio of 57.85, a P/E/G ratio of 2.54 and a beta of 0.89. The stock has a 50 day moving average price of $93.13 and a 200-day moving average price of $86.47. LeMaitre Vascular has a 52-week low of $51.70 and a 52-week high of $106.99.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company’s revenue was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.33 earnings per share. On average, analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Insider Activity at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. This represents a 62.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.79% of the stock is currently owned by insiders.

Institutional Trading of LeMaitre Vascular

A number of institutional investors and hedge funds have recently made changes to their positions in LMAT. NBC Securities Inc. increased its position in shares of LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 183 shares during the period. GAMMA Investing LLC lifted its position in shares of LeMaitre Vascular by 57.0% during the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 199 shares in the last quarter. West Oak Capital LLC bought a new position in shares of LeMaitre Vascular during the second quarter valued at about $58,000. USA Financial Formulas bought a new position in shares of LeMaitre Vascular during the third quarter valued at about $60,000. Finally, nVerses Capital LLC increased its holdings in LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 200 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.